Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

In the Relevant Event issued on 27 October 2018, Grifols informed about the results obtained in the AMBAR (Alzheimer Management by Albumin Replacement) clinical trial (phase IIb/III), which were reported at the "Clinical Trials on Alzheimer's Disease" congress in Barcelona.

Grifols informs that additional results of its AMBAR clinical trial has been presented today at the 14th International Congress on Alzheimer's and Parkinson's Disease in Lisbon. These results complement and confirm those presented in October.

Grifols plans to offer updates for the remainder of 2019 at various scientific congresses and expects to have all the analyses mentioned in the study available in December.

In Barcelona, on 29 March 2019

Nuria Martín Barnés
Secretary to the Board of Directors